Epicypher, Inc. — Department of Health and Human Services SBIR Phase II: 400

Epicypher, Inc. — SBIR Phase II award from Department of Health and Human Services.

Amount
$1,499,995
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase II
Topic
400
Solicitation
PA16-302
NAICS
Place of performance
NC
Period
2017-08-01 → 2019-07-31

Description

PROJECT SUMMARYEpigeneticregulatorsrepresentanewfrontierindrugdiscoveryandarerapidlyattractingpharmaceuticalinterestsduetotheirremarkabledruggabilityandstrongconnectionwithhumandiseasese gmetabolicsyndromesneurodegenerativedisordersandcancersTodatetheepigenomeconsistsofoverknownproteinsHoweververyfewepigeneticmodifiersarebeingpursuedindrugdevelopmentprograms due to our limited understanding of what proteins these enzymes regulateThis narrow saturation oftheepigeneticdrugarenaisfueledbyadearthoftoolstosystematicallyidentifyandcharacterizepotentialtargetsTo aid in the discovery of novel relationships between enzymes and the proteins that they targetwe willcommercializehighcomplexityorientedpeptidearraylibrariesOPALsInPhaseIstudieswesynthesizedOPALlibrariescomprisingacorearginineROPALorlysineKOPALresiduewithflankingdegeneratesequencesoraminoacidsinbothNandCterminaldirectionsFigureanddemonstratedthatOPALsarepowerfultoolstosystematicallycharacterizetargetmotifsofwriterenzymesOurfocushereistodevelop OPALs to examinewriterenzymes that modify lysine or arginine residuesIn Phase IIEpiCypher willscale up synthesis of the unmodified KOPAL and ROPAL peptide libraries and optimize a highthroughputwell assay format for validation using methyltransferase assays developed in the Phase I studiesAimWewillalsovastlyexpandthecommercialutilityofourdiscoveryplatformontwofrontsdevelopinganonradioactive detection system and a userfriendly data analysis pipeline establishingAimandexpandingour KOPAL platform to analyze lysineacylation writer enzymesAimSeven additional lysinemodified acylgroupposttranslationalmodificationsofwhichacetylationisafoundingmemberhavebeenrecentlyidentifiede gcrotonylationbutyrylationor propionylationwhich function together with lysine acetylation toregulategeneactivationGiventhewelldescribedroleofhistoneacetylationindiseasethesenewacylationPTMsrepresentanexcitingnewfieldofepigeneticstudythathasgreatdrugdevelopmentpotentialTheinnovativediscoveryplatformdescribedhereinprovidesthefirstcomprehensivescreeningtooltostudyepigeneticwriterenzymesEpiCypherhasassembledastrongscientificteamconsistingofpioneersinthefieldofepigeneticregulationDrsMarkBedfordandScottRothbartanddetectionchemistryDrMarceyWaterstodeveloparobustversatileanduserfriendlydiscoveryplatformthatwillhaveapowerfultranslational impact on epigenetic research and therapeutic development